Menovo(SH:603538) Jing Ji Guan Cha Wang·2026-02-13 09:14Group 1 - Core viewpoint: Meinuo Pharma (603538) announced that its wholly-owned subsidiary, Meinuo Tiankang, is participating in the national centralized procurement bidding, with ten products including Perindopril tert-butylamine tablets expected to be selected, covering cardiovascular and anti-infection fields [1] - Expected sales: The total sales for the first three quarters of 2025 are projected to be 71.75 million yuan, accounting for 6.4% of the company's revenue during the same period [1] - Implementation timeline: The selection results are expected to be implemented by the end of March 2026, with the procurement cycle lasting until the end of 2028 [1] Group 2 - Recent stock performance: Over the past seven trading days (from February 6 to February 13, 2026), Meinuo's stock price fluctuated within a range of 4.90%, with the latest closing price at 21.18 yuan, reflecting a slight increase of 0.76% compared to February 6 [2] - Capital flow: On February 13, the net outflow of main funds was 2.2299 million yuan, while retail funds saw a net inflow; the turnover rate remained stable between 1% and 3% [2] - Market comparison: The overall performance of Meinuo was slightly better than the chemical pharmaceutical sector, which saw a decline of 0.97%, but weaker than the overall market index [2]